Сывороточный Her-2/neu у больных первичным раком молочной железы
Диссертация
Значение рецепторов семейства РЭФР (HER) в развитии опухоли доказано как экспериментальными, так и клиническими исследованиями. Внедрение гена HER-2 в молочные железы трансгенных мышей приводит к развитию раковых опухолей (99). Определение статуса HER-2/ием проводится больным распространенным РМЖ с целью выявления группы больных, подлежащих таргетной терапии Герцептином (трастузумабом)(120). Ряд… Читать ещё >
Список литературы
- Герштейн Е.С., Кушлинский Н. Е. Современные представления о механизмах передачи сигналов факторов роста как основа эффективной молекулярно-направленной противоопухолевой терапии. Вопросы биологической, медицинской и фармацевтической химии, 2007, № 1
- Давыдов М.И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2004г. Вестник РОНЦ им. Н. Н. Блохина РАМН 2006, 3 том 17 прил. 1 стр 12−14.
- Кушлинский Н.Е. Тканевые маркеры как факторы прогноза при раке молочной железы. Практическая онкология: избранные лекции. Под ред. С. А. Тюляндина и В. М. Моисеенко. «Центр ТОММ», Ст.-Петербург, 2004, с. 41−50.
- Летягин В.П. Первичные опухоли молочной железы М. «Миклош» 2004 332стр.
- Aaronson SA. Growth factors and cancer. Science 1991 -254:1146−1153.
- Aguilar Z, Slamon DJ. The transmembrane heregulin precursor is functionally active. J Biol Chem 2001−276:44 099−44 107.
- Ali SA, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, et al. Relationship of serum HER-2/яеи and serum CA 15−3 in patients with metastatic breast cancer. Clin Chem 2002−48:1314−1320.
- Andersen TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL. Detection of c-erbB-2 related protein in sera from breast cancer patients. Acta Oncol 1995−34:499−504.
- Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J. 2005 Jul-Aug-ll (4):278−80.
- Arnould L, Denoux Y, MagGrogan G, Penault-Liora F, Fiche M, Treil-leaux I. Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of HER2 status in breast cancer. Int J of Cancer 2003−88:1587−1591.
- Bane AL, Tjan S, Parkes RK, et al. Invasive lobular carcinoma: to grade or not to grade.// Mod Pathol. 2005 May-18(5):621−8.
- Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor related protein. Nature 1986−319:226−230.
- Benny Vittrup Jensen, Julia S. Johansen and Paul A. Price High Levels of Serum HER-2/neu and YKL-40 Independently Reflect Aggressiveness of Metastatic Breast Cancer Clinical Cancer Research Vol. 9, 4423−4434, October 1, 2003
- Berns EM, Foekens JA, van Putten WL, van Staveren IL, Portengen H, de Koning WC, Klijn JG. Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification. J Steroid Biochem Mol Biol. 1992 Sep-43(l-3):13−9.
- Blackwell KL, Burstein H, Pegram M et al. Determining relevant bio-markers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J Clin Oncol 2005−23
- Brandt-Rauf PW, Pincus MR, Carney WP. The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog. 1994−5(2−3):313−29.
- Breuer B, DeVivo I, Luo JC, Smith S, Pincus MR, Taturn AH, et al. ErbB-2 and myc oncoproteins in sera and tumors of breast cancer patients. Cancer Epidemiol Biomarkers Prev 1994−3:63−66.
- Breuer B, Luo JC, DeVivo I, Pincus M, Tatum AH, Daucher J, et al. Detection of elevated c-erbB-2 oncoprotein in the serum and tissue in breast cancer. Med Sci 1993−21:383−384.
- Breuer B, Smith S, Thor A, Edgerton S, Osborne MP, Minck R, et al. ErbB-2 protein in sera and tumors of breast cancer patients. Breast Cancer Res Treat 1998−49:261−270.
- Carney WP. The emerging role of monitoring serum HER-2/"ew oncoprotein levels in women with metastatic breast cancer. Lab Med 2003−34:58−64.
- Carney WP, Hamer PJ, Petit D, Retos C, Greene R, Zabrecky JR, et al. Detection and quantitation of the human neu oncoprotein. J Tumor Marker Oncol 1991−6:53−72.
- Chearskul S, Bhothisuwan K, Ornrhebroi S, Sungkabunchoo S, Sinlarat P, Churintrapun M, et al. Serum c-erbB-2 protein in breast cancer patients. J Med Assoc Thai 2000−83:886−893.
- Cheung KL, Pinder SE, Paish C, Sadozye AH, Chan SY, Evans AJ, et al. The role of blood tumor marker measurement (using a biochemical index score and c-erB2) in directing chemotherapy in metastatic breast cancer. Int J Biol Markers 2000−15:203−209.
- Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, et al. NH2-terminally truncated HER-2/"ew protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998−58:5123−5129.
- Classen S, Kopp R, Possinger K, Weidenhagen R, Eiermann W, Wil-manns W. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second line hormone or chemotherapy. Tumor Biol 2002−23:70−75.
- Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000−6:2356−2362.
- Cook GB, Neamann IE, Goldblatt JL, Cambetas DR, Hussain M, Liiflt-ner D, et al. Clinical utility of serum HER-2/"ew testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 2001−21:1465−1470.
- Correa P, Johnson W. International variation in the histology of breast carcinoma. UICC Tech Rep Ser 1978−35:36−65.
- Coussens L, Yang-Feng TL, Liao Y-C, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptorshares chromosomal location with neu oncogene. Science 1985−230:1132−1139.
- Dandaci N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER-2 oncogene in archival human breast carcinoma. Lab Invest 2002−82:1007−1014.
- Dickman S. Antibodies stage a comeback in cancer treatment. Science 1998−280:1196−1197.
- Dittadi R, Zancan M, Perasole A, Gion M. Evaluation of HER-2/wew in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int J Biol Markers 2001- 16:255 261.
- Dnistrian AM, Schwartz MK, Schwartz DC, Ghani F, Kish L. Significance of serum HER-2/"ew oncoprotein, CA 15−3 and CEA in the clinical evaluation of metastatic breast cancer. J Clin Ligand Assay 2003−25:215−220.
- Ellis I O, Bartlett J et. al. Journal of Clinical Pathology 2004−57:233−237
- Eskelinen M, Kataja V, Hamalainen E, Kosma VM, Penttila I, Alhava E. Serum tumor markers CEA, AFP, CA15−3, TPS and neu in diagnosis of breast cancer. Anticancer Res 1997−17:231−234.
- Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002−20:1800−1808.
- Fehm T, Gebauer G, Jager W. Clinical utility of serial serum c-erB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Treat 2002−75:97−106.
- Fehm T, Jager W, Kraemer S, Sohn C, Solomayer-Meyberg G, Solo-may er EF, Kurek R, Wallwiener D, Gebauer G. Changes of serum HER2 status during clinical course of metastatic breast cancer patients. Anticancer Res. 2004 Nov-Dec-24(6):4205−10.
- Fehm T, Maimonis P, Katalinic A, Jager W. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 1998−55:33−38.
- Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jager W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997−43:87−95.
- Fontana X, Ferrari P, Namer M, Peysson R, Salanon C, Bussiere F. C-erbB2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis. Anticancer Res 1994−14:2099−2104.
- Gancberg D, DiLeo A, Cardoso F, Rouas G, Pedrocchi M, Paesmanns M, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002- 13:10 361 043.
- Goldhirsch A, Glick J. H., Gelber R. D., Coates A. S., Thurlimann B., Senn H.-J. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 Annals of Oncology 2005 16(10): 1569−1583.
- Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992−10:1049−1056.
- Hait WN. The prognostic and predictive values of ECD-HER-2. Clin Cancer Res 2001−7:2601−2604.
- Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol. 2000 Jun-l 1(6):647−63.
- Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001−19:1698−1706.
- Harris LN, Lueftner D, Jager W, Robertson JFR. C-erbB-2 in serum of patients with breast cancer. Int J Biol Markers 1999−14:8−15.
- Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002−29:231−245.
- Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, et al. Circulating HER-2/erbB-2/c-wew (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast. Clin Cancer Res 2001−7:2703−2711.
- Henry N. L., Hayes D. F. Uses and Abuses of Tumor Markers in the Diagnosis, Monitoring, and Treatment of Primary and Metastatic Breast Cancer The Oncologist, Vol. 11, No. 6, 541−552, June 2006
- Hoopmann M, Neumann R, Tanasale T, Schondorf T. HER-2Ineu determination in blood plasma of patients with HER-2/wew overexpressing metastasized breast cancer: a longitudinal study. Anticancer Res 2003−23:1031−1034.
- Hosono M, Saga T, Sakahara H, Kobayashi H, Shirato M, Endo K, et al. Construction of immunoradiometric assay for circulating c-erbB-2 protooncogene product in advanced breast cancer patients. Jpn J Cancer Res 1993−84:147−152.
- Imoto S, Kitoh T, Hasebe T. Serum c-erbB-2 levels in monitoring of operable breast cancer patients. Jpn J Clin Oncol 1999−29:336−339.
- Isola JJ, Holli K, Oksa H, Teramoto Y, Kallioniemi OP. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 1994−73:652−658.
- Kandl H, Seymour L, Bezwoda WR. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994−70:739−742.
- Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol. 2001 Sep-10(3):139−52.
- Kath R, Hoffken K, Otte C, Metz K, Scheulen ME, Hulskamp F, et al. The «ew-oncogene product in serum and tissue of patients with breast carcinoma. Ann Oncol 1993−4:585−589.
- Klein B, Levin I, Kfir B, Marinski R, Rakowski E, Shapira J, et al. Soluble c-erbB-2 (PI85) in breast cancer patients in relation to prognosis. Oncol Rep 1995−2:759−761.
- Koestler WJ, Schwab B, Singer C, Neumann R, Marton E, Brodowicz T, et al. Predictive value of serum HER-2/"ew extracellular domain (ECD) during trastuzumab-based therapies Abstract. Proc Am Assoc Cancer Res 2002−43:201.
- Konecny GE, Thomssen C, Luck HJ et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004- 96: 1141−1151.
- Kong SY, Kang JH, Kwon Y, Kang HS, Chung KW, Kang SH, Lee DH, Ro J, Lee ES. Serum HER-2 concentration in patients with primary breast cancer. J Clin Pathol. 2006 Apr-59(4):373−6.
- Krainer M, Brodowicz T, Zeillinger R, Wiltschke C, Scholten C, Seifert M, et al. Tissue expression and serum levels of HER-2/"ew in patients with breast cancer. Oncology 1997−54:475−481.
- Kurebayshi J. Biological and clinical significance of HER2 overexpression in breast cancer. Breast Cancer 2001−8:45−51.
- Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, et al. Determination of a fragment of the c-erbB-2 fragment translational product pi 85 in serum of breast cancer patients. Cancer Res Clin Oncol 1993−119:249−252.
- Latta EK, Tjan S, Parkes RK, O’Malley FP. The role of HER-2/"ew overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 2002−15:1318−1325.
- Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a preparation of breast cancer patients. J Clin Oncol 1992−10:436−443.
- Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, et al. Elevated serum HER-2?neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002−20:1467−1472.
- Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA. Serum HER-2/rcew and response to the aromatase inhibitor Letro-zole versus Tamoxifen. J Clin Oncol 2003−21:1967−1972.
- Luftner D, Luke C, Possinger K. Serum HER-2/neu in the management of breast cancer patients. Clin Biochem. 2003 Jun-36(4):233−40
- Lueftner D, Schnabel S, Possinger K. c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy. Int J Biol Markers 1999−14:55−59.
- Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 1979−3:467−488.
- Mass RD, Proc Am Soc Clin Oncol, abstract 19, 2000
- McKeage K, Perry CM. Trastuzumab. A review of its use in the treatment of metastatic breast cancer overexpressing HER-2. Drugs 2002−62:209−243.
- McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali D, Trimpe KL, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, pl85. Oncogene 1989−4:43−48.
- Mehta RR, McDermott JH, Heiken TJ, Marler KC, Patel MK, Wild LD, et al. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol 1998−16:2409−2416.
- Mocanu M.M., Fazekas Z., Petras M. et al. Associations of ErbB2, betal-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines // Cancer Lett.-2005.-Vol. 227 (2).-P. 201 212.
- Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M, et al. Serum levels of c-erbB-2 (HER-2/wew) in patients with malignant and non-malignant diseases. Tumor Biol 1997−18:188−196.
- Molina R, Jo J, Filella X, Zanon G, Farrus B, Munoz M, et al. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence in breast cancer patients. Anticancer Res 1999−19:2551−2556.
- Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res 1996−16:2295−2300.
- Molina R, Jo J, Zanon G, Filella X, Farrus B, Munoz M, et al. Utility of c-erbB-2 in tissue and serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. Br J Cancer 1996−74:1126−1131.
- Moy B., Goss P. Lapatinib: Current Status and Future Directions in Breast Cancer The Oncologist, Vol. 11, No. 10, 1047−1057, Nov 2006
- Muller W.J., Sinn E., Pattengale P.K. et al. Single-step induction of mammary adenocarcinoma in transgenic mice is bearing the activated c-neu oncogenes // Cell. 1988. — Vol.54. — P. 105−115
- Nagy P., Friedlander E., Tanner M. et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line // Cancer Res.-2005.-Vol. 65 (2).-P. 473−482.
- Narita T, Funahashi H, Satoh Y, Takagi H. C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 1992−24:97−102.
- Nugent A, McDermott E, Duffy K, O’Higgins N, Fennelly JJ, Duffy MJ. Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer. Clin Chem 1992−38:1471−1474.
- Nunes RA, Harris LN. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 2002−3:125−135.
- Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist. 2004−9(4):361−77
- Pallud C, Guinebretiere JM, Guepratte S, Hacene K, Neumann R, Carney W, Pichon MF. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. Anticancer Res. 2005 Mar-Apr-25(2B): 1433−40.
- Payne RC, Allard JW, Anderson-Mauser L, Humphreys JD, Tenney DY, Morris DL. Automated assay for HER-2Ineu in serum. Clin Chem 2000−46:175−182.
- Pegram M, Hsu S, Lewis G. Inhibitory effects of combinations of HER-2Ineu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999−18:2241−2251.
- Pegram MD, Finn RS, Arzoo K. The effect of c-erbB-2 HER-2/wew overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997−15:537−547.
- Penault-Llorca F. Comments on the new American Joint Committee on Cancer TNM staging for breast cancer. What’s new for the pathologist? Ann Pathol. 2003 Dec-23(6):492−5.
- Pichon MF, Hacene K, Guepratte S, Neumann R. Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients. Clin Lab. 2004- 50 (3−4): 163−70.
- Price-Schiavi S.A., Jepson S., Li P. et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance // Int J Cancer.-2002.-Vol. 99 (6
- Pritchard KI, Shepherd LE, O’Malley FP, Andrulis IL, Tu D, Bramwell- VH, Levine MN- HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl J Med. 2006 May 18−354(20):2103−11
- Pro well TM, Armstrong DK. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play? Semin Oncol. 2006 Dec-33(6):681−7.
- Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993−8:2917−2923.
- Reddy JC, Reimann JD, Anderson SM, Klein PM. Concordance between central and local laboratory HER2 testing from a community-based, clinical study. Clin Breast Cancer. 2006 Jun-7(2): 153−7
- Revillion F, Hebbar M, Bonneterre J, Peyrat JP. Plasma c-erbB2 concentrations in relation, to chemotherapy in breast cancer patients. Eur J Cancer 1996−32A:231−234.
- Ross JS, Fletcher JA. HER-2/wew (c-erbB2) gene and protein in breast cancer. Am J Clin Pathol 1999−112:S53-S67.
- Ross JS, Fletcher JA, Linette GP et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003−8:307−325
- Rundhaug JE. The biology behind matrix metalloproteinases, angio-genesis and cancer. Clin Cancer Res 2003−9:551−554.
- Schaller G, Evers K, Papadopoulos S, Ebert A, Buhler H. Current use of HER2 tests. Ann Oncol 2001−12:S97-S100.
- Schoendorf T, Hoopmann M, Warm M, Neumann R, Thomas A, Gohring UJ, et al. Serologic concentrations of HER-2/wew in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course. Clin Chem 2002−48:1360−1362.
- Schwartz MK, Smith C, Schwartz DC, Dnistrian A, Neiman I. Monitoring therapy by serum HER-2/"ew. Int J Biol Markers 2000−15:324−329.
- Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004- 96: 926−935.
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/"^ oncogene. Science 1987−235:177−182.
- Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2"ew proto-oncogene in human breast and ovarian cancer. Science 1989−244:707−712.
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001−344:783−792.
- Streckfus C, Bigler L, Dellinger T, Dali X, Kingman A, Thigpen JT. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res 2000−6:2363−2370.
- Sugano K, Kawai T, Ishii M, Koyama H, Kitajima M, Kasumi F, et al. Clinical evaluation of serum ErbB-2 protein using enzyme immunoassay (ErbB-2 EIA Nichirei.). Gan To Kagaku Ryoho 1994−21:1255−1262.
- Sugano K, Ushiama M, Fukutomi T, Tsuda H, Kitoh T, Ohkura H. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer 2000−89:329−333.
- Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organisation of Classification of Tumours. IARC Press: Lyon, 2003.
- Tsai CM, Yu D, Chang KT, Wu LH, Perng PR, Ibrahim NK, et al. Enhanced chemoresistance by elevations of the levels of pi 85 neu in the HER-2/wew-transfected human lung cancer cells. J Natl Cancer Inst 1995−87:682−684.
- Visco V, Bei R, Moriconi E, Gianni W, Kraus MH, Muraro R. ErbB2 immune response in breast cancer patients with soluble receptor ecto-domain. Am J Pathol 2000−156:1417−1424.
- Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer. J Clin Oncol 2002−20:719−726.
- Volas GH, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A. Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer 1996−78:267−272.
- Watanabe N, Mityamoto M, Tokuda Y, Kubota M, Ando Y, Tajima T, et al. Serum c-erbB-2 in breast cancer patients. Acta Oncol 1994−33:901−904.
- Willsher PC, Beaver J, Pinder S, Bell JA, Ellis IO, Blarney RW, et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996−40:251−255.
- Wright C, Cairns J, Cantwell BJ, Hall AG, Harris AL, Home CH. Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione-transferases. Br J Cancer 1992−65:271−274.
- Wu JT, Astill ME, Gagon SD, Bryson L. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein. J Clin Lab Anal 1995−9:151−165.
- Wu JT, Astill ME, Zhang P. Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J Clin Lab Anal 1993−7:31−40.
- Wu Y, Khan H, Chillar R, Vadgama J. Prognostic value of plasma HER-2Ineu in African American and Hispanic women with breast cancer. Int J Oncol 1999−14:1021−1037.
- Yu D, Jing T, Liu B. Overexpression of Erb2 blocks taxol-induced apoptosis by upregulation of p21Cipl, which inhibits p34 Cdc2 kinase. Mol Cell 1998−2:581−591.
- Yuan P, Xu BH, Chu DT. Correlation between serum HER-2 oncoprotein and patients with breast cancer. Chin Med Sci J. 2004 Sep-19(3):212−5.
- Yuste L., Montero J.C., Esparis-Ogando A., Pandiella A. Activation of ErbB2 by overexpression or by transmembrane neuregulin results indifferential signaling and sensitivity to herceptin // Cancer Res.-2005.-Vol. 65 (15).-P. 6801−6810.
- Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of pi 85 is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991−266:1716−1720.